Clay Siegall is known as the founder and the present chief executive officer of the pharmaceutical company called Seattle Genetics. The company is headquartered in Seattle, Washington, and under the leadership of Clay Siegall, Seattle Genetics managed to become one of the most successful pharmaceutical companies in the region. Clay Siegall is a striving entrepreneur who is working hard to have his company recognized nationally. For now, he is enjoying the statewide exposure for his business, but he wanted Seattle Genetics to be known all throughout the United States as well. He knows that by tapping the national market, more business opportunities would come right at his door. The company was founded in 1988, and Clay Siegall stated that his primary objective of creating a pharmaceutical company is to create a drug that will eradicate several diseases that threaten the existence of humanity. They listed cancer as their top priority, and he built a team comprising of chemists, pharmacists, biologists and researchers who will study the nature of some pathogens and develop a way on how to finish them off.
Through years of research, Seattle Genetics managed to develop a drug that was recently approved by the Food and Drug Administration. The drug is known as Adcetris, and it is used to cure Hodgkin lymphoma, which is a type of cancer in the lymphatic system that becomes deadly if not treated. Hodgkin lymphoma causes the immune system to deteriorate, and it will be incapable its victim from doing anything and causing them to experience daily fatigue. Adcetris treats patients detected with Hodgkin lymphoma, and the company has recorded cases in which the patient recovered. Aside from Adecetris, Clay Siegall is also proud to present three other drugs that are waiting to be approved by the Food and Drug Administration. These are 33A, 22ME, and LIV1, and these drugs are used to treat myeloid leukemia, bladder cancer, and breast cancer, respectively.
The leadership of Clay Siegall made Seattle Genetics as one of the fastest growing companies in America. Their stock prices grew significantly, and the company is now valued at $10 billion. According to Clay Siegall, they are planning to hire more employees, and he recently opened up an office in Switzerland, in high hopes that the company will also become an international player in the pharmaceutical industry.